Sign In
Search Icon
Menu Icon


ASPR/CDC Mpox Vaccination Operational Planning Guide - HHS Mpox Vaccination Program

The goal of the distribution strategy is to support equitable access to vaccines for people who are disproportionately affected by mpox.

63 jurisdictions and 8 federal entities, including IHS, HRSA, Ryan White clinics, and VA, can request shipments from their allocations of JYNNEOS vaccine, or can also request ACAM2000 vaccine, which is available in much greater supply but carries a risk for severe adverse events in certain populations.

  • To date, HHS has made approximately 1.1 million vials available to jurisdictions and federal entity partners, and more than 835,000 vials have been ordered. 
Date Initiated
Vials allocated to jurisdictions
June 2022 56,000 SC
July 2022 144,000 SC Completed
July/August 2022
383,8569 ID or SC Completed
August 2022
360,000 ID or SC Transition to Threshold  January 9
Total  =  943,85610  vials    

  • Jurisdictions were required to sign the data use agreement or DUA, prior to placing Phase 3 orders and should continue inputting their aggregate inventory and administration counts weekly.
  • HHS is moving away from phased allocations and transitioning to a jurisdictional threshold approach by January 9th. Note, similar threshold approaches are used for COVID-19 vaccines and TPOXX distribution.
  • The threshold calculation is based exclusively on each jurisdiction’s estimated percentage of the nation’s population for whom JYNNEOS vaccination is currently recommended. For example, if 5% of the recommended population lives in a particular jurisdiction, that jurisdiction’s threshold will be 5% of the total number of vials available under the threshold.
  • To ensure that no jurisdiction has access to fewer vials as a result of this transition to thresholds, if the calculated threshold for a given jurisdiction is less than the number of vials it has available.
  • Available vials in HPOP
    as of December 12th
    Threshold estimate Final threshold calculation <





  • ASPR continues to closely monitor the outbreak and work with jurisdictions and federal entity partners to ensure sufficient supply.

FDA authorized the JYNNEOS vaccine under an EUA on August 9, 2022. This change occurred during phase 3 and allowed for administration via the intradermal (ID) route in addition to subcutaneous (SC). Accounting for the change in route, ASPR estimates ~313,500 SC only doses during Phase Tranche 3a and up to 5 ID doses/vial during Tranches 3b and c.

10 Total includes vials distributed to jurisdictions to date and does not include distributions made to federal entity partner or the special events.